| CARLAT PUBLISHING

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

Patients receiving buprenorphine for opioid use disorder are typically also referred for psychotherapy, either individual or group. However, several studies have failed to show that therapy improves outcomes in buprenorphine treatment program Read More

MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder

Ms. Petitt’s manages the program that selects and trains researchers for the MDMA-assisted psychotherapy protocols MAPS Public Benefit Corporation is conducting. The program has reviewed 300 applicants, and is in the midst of training 80 people who will work on therapy teams for Phase 3 trials. In addition to the training program, Ms. Petitt has also served as co-therapist on the MAPS-sponsored Phase 2 trial of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness. Read More

From the Street to the Prescription Pad: Psychedelics Return to Psychiatry

As marijuana has gained acceptance—it can now be prescribed to treat a wide variety of medical conditions in 28 states and Washington, DC—there has also been a shift in attitudes toward other mind-altering substances that, despite their reputation as drugs of abuse, show promise as therapeutic agents. Read More

Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)
The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

Addiction Treatment
Supervised Drug Consumption Sites
Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.
Listen now